{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:59:00Z","timestamp":1777067940565,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1007\/s11883-004-0096-4","type":"journal-article","created":{"date-parts":[[2007,5,22]],"date-time":"2007-05-22T21:50:43Z","timestamp":1179870643000},"page":"94-100","source":"Crossref","is-referenced-by-count":2,"title":["Is the use of unfractionated heparin in acute coronary syndrome outmoded?"],"prefix":"10.1007","volume":"6","author":[{"given":"Elaine","family":"Chiquette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Chilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"96_CR1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","volume":"324","author":"J Hirsh","year":"1991","unstructured":"Hirsh J, Heparin: N Engl J Med 1991, 324:1565\u20131574.","journal-title":"N Engl J Med"},{"key":"96_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","volume":"96","author":"W Klein","year":"1997","unstructured":"Klein W, Buchwald A, Hillis SE, et al.: Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997, 96:61\u201368.","journal-title":"Circulation"},{"key":"96_CR3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","volume":"337","author":"M Cohen","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP, et al., for the Efficacy and Safety of subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group: A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447\u2013452.","journal-title":"N Engl J Med"},{"key":"96_CR4","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","volume":"100","author":"EM Antman","year":"1999","unstructured":"Antman EM, Cohen M, Radley DR, et al., for the TIMI-11B and ESSENCE Investigators: Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q wave myocardial infarction: TIMI-11B-ESSENCE meta-analysis. Circulation 1999, 100:1602\u20131608.","journal-title":"Circulation"},{"key":"96_CR5","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","volume":"100","author":"E Antman","year":"1999","unstructured":"Antman E, Cohen M, Radley D, et al.: Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999, 100:1602\u20131608.","journal-title":"Circulation"},{"key":"96_CR6","unstructured":"Simmoons M: PENTUA results. Paper presented at the American Heart Association meeting. Anaheim, CA; 2001."},{"key":"96_CR7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0002-8703(03)00179-0","volume":"146","author":"LK Michalis","year":"2003","unstructured":"Michalis LK, Katsouras CS, Papamichael N, et al.: Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: The EVET trial. Am Heart J 2003, 146:304\u2013310.","journal-title":"Am Heart J"},{"key":"96_CR8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0167-5273(99)00171-0","volume":"71","author":"M Cohen","year":"1999","unstructured":"Cohen M, Theroux P, Weber S, et al.: Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999, 71:273\u2013281.","journal-title":"Int J Cardiol"},{"key":"96_CR9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","volume":"107","author":"SG Goodman","year":"2003","unstructured":"Goodman SG: Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide. Circulation 2003, 107:238\u2013244.","journal-title":"Circulation"},{"key":"96_CR10","unstructured":"Ferguson JJ, Antman E, Bates E, et al.: The Use of Enoxaparin and IIb\/IIIa Antagonists in Acute Coronary Syndromes, including PCI. Abstract presented at the European Congress of Clinical Cardiology. 2000."},{"key":"96_CR11","first-page":"272","volume":"4","author":"DJ Kereiakes","year":"2001","unstructured":"Kereiakes DJ, Grines C, Fry E, et al., for the NICE-1 and NICE-4 Investigators: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001, 4:272\u2013278.","journal-title":"J Invasive Cardiol"},{"key":"96_CR12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/hc3101.093866","volume":"104","author":"AM Ross","year":"2001","unstructured":"Ross AM, Molhoek P, Lundergan C, et al.: Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001, 104:648\u2013652.","journal-title":"Circulation"},{"key":"96_CR13","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","volume":"105","author":"EM Antman","year":"2002","unstructured":"Antman EM; Louwerenburg HW, Baars HF, et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002, 105:1642\u20131649.","journal-title":"Circulation"},{"key":"96_CR14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/euhj.2001.3083","volume":"23","author":"M Simoons","year":"2002","unstructured":"Simoons M, Krzeminska-Pakula M, Alonso A, et al.: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002, 23:1282.","journal-title":"Eur Heart J"},{"key":"96_CR15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0735-1097(98)00612-3","volume":"33","author":"G Frostfeldt","year":"1999","unstructured":"Frostfeldt G, Ahlberg G, Gustafsson G, et al.: Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction\u2014a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999, 33:627\u2013633.","journal-title":"J Am Coll Cardiol"},{"key":"96_CR16","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/euhj.2001.2777","volume":"22","author":"PK Coussement","year":"2001","unstructured":"Coussement PK, Bassand JP, Convens C, et al., for the Fentalyse investigators: A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001, 22:1716\u20131724.","journal-title":"Eur Heart J"},{"key":"96_CR17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0195-668X(03)00006-X","volume":"24","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Bergstrand L, Dellborg M, et al.: Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction\u2014the ASSENT Plus study. Eur Heart J 2003, 24:897\u2013908.","journal-title":"Eur Heart J"},{"key":"96_CR18","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358:605\u2013613.","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"96_CR19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","volume":"108","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Goldstein P, Armstrong PW, et al.: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Plus randomized trial in acute myocardial infarction. Circulation 2003, 108:135\u2013142.","journal-title":"Circulation"},{"issue":"5A","key":"96_CR20","first-page":"10G","volume":"88","author":"JL Martin","year":"2001","unstructured":"Martin JL, Fry ET, Sanderink G, et al., for the PEPCI Study: Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes. The PEPCI study [abstract]. Am J Cardiol 2001, 88(5A):10G-11G.","journal-title":"Am J Cardiol"},{"key":"96_CR21","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","volume":"103","author":"JP Collet","year":"2001","unstructured":"Collet, JP, Montalescot G, Lison L, et al.: Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001, 103:658\u2013663.","journal-title":"Circulation"},{"key":"96_CR22","doi-asserted-by":"crossref","unstructured":"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC-II prospective randomised multicenter study. FRagmin and Fast Revascularization during InStability in Coronary artery disease investigators. Lancet 1999, 354:708.","DOI":"10.1016\/S0140-6736(99)07349-3"},{"key":"96_CR23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-9149(02)02517-1","volume":"90","author":"KA Fox","year":"2002","unstructured":"Fox KA, Antman EM, Cohen M, et al.: Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris\/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 2002, 90:477\u2013482.","journal-title":"Am J Cardiol"},{"key":"96_CR24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(02)09894-X","volume":"360","author":"KA Fox","year":"2002","unstructured":"Fox KA, Poole-Wilson PA, Henderson RA, et al.: Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002, 360:743\u2013751.","journal-title":"Lancet"},{"key":"96_CR25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1067\/mhj.2001.113217","volume":"141","author":"DJ Kereiakes","year":"2001","unstructured":"Kereiakes DJ, Kleiman NS, Fry E, et al.: Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001, 141:348\u2013352.","journal-title":"Am Heart J"},{"key":"96_CR26","first-page":"272","volume":"4","author":"DJ Kereiakes","year":"2001","unstructured":"Kereiakes DJ, Grines C, Fry E, et al., for the NICE-1 and NICE-4 Investigators: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001, 4:272\u2013278.","journal-title":"J Invasive Cardiol"},{"key":"96_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","volume":"352","author":"The EPISTENT Investigators","year":"1998","unstructured":"The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb\/IIIa blockade. Lancet 1998, 352:87\u201392.","journal-title":"Lancet"},{"key":"96_CR28","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","volume":"336","author":"The EPILOG Investigators","year":"1997","unstructured":"The EPILOG Investigators: Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689\u20131696.","journal-title":"N Engl J Med"},{"key":"96_CR29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/hc2901.094150","volume":"104","author":"DL Bhatt","year":"2001","unstructured":"Bhatt DL, Lincoff AM: Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: the results of the CRUISE trial. Circulation 2001, 104:384\u2013385.","journal-title":"Circulation"},{"key":"96_CR30","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(02)02531-7","volume":"40","author":"R Choussat","year":"2002","unstructured":"Choussat R, Montalescot G, Collet JP, et al.: A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002, 40:1943\u20131950.","journal-title":"J Am Coll Cardiol"},{"key":"96_CR31","first-page":"235","volume":"15","author":"L Carnendran","year":"2003","unstructured":"Carnendran L, Borkowski R, Markabawi B, Warner MF: Safety and efficacy of low-dose intravenous enoxaparin and glycoprotein IIb\/IIIa inhibitor therapy during percutaneous coronary interventions. J Invasive Cardiol 2003, 15:235\u2013238.","journal-title":"J Invasive Cardiol"},{"key":"96_CR32","first-page":"247","volume":"14","author":"L Miller","year":"2002","unstructured":"Miller L, Gupta A, Bertolet BD: Use of clopidogrel loading, enoxaparin, and double bolus eptifibatide in the stetting of early percutaneous coronary intervention for acute coronary syndromes. J Invasive Cardiol 2002, 14:247\u2013250.","journal-title":"J Invasive Cardiol"},{"key":"96_CR33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/ajhp\/59.suppl_6.S7","volume":"59","author":"EA Nutescu","year":"2002","unstructured":"Nutescu EA: Am J Health Syst Pharm 2002, 59:123\u2013126.","journal-title":"Am J Health Syst Pharm"},{"key":"96_CR34","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","volume":"337","author":"JI Weitz","year":"1997","unstructured":"Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997, 337:688\u2013698.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-004-0096-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-004-0096-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-004-0096-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:35:26Z","timestamp":1559432126000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-004-0096-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1007\/s11883-004-0096-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}